ATE192045T1 - Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose - Google Patents

Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose

Info

Publication number
ATE192045T1
ATE192045T1 AT93906071T AT93906071T ATE192045T1 AT E192045 T1 ATE192045 T1 AT E192045T1 AT 93906071 T AT93906071 T AT 93906071T AT 93906071 T AT93906071 T AT 93906071T AT E192045 T1 ATE192045 T1 AT E192045T1
Authority
AT
Austria
Prior art keywords
multiple sclerosis
treatment
adenine derivatives
substituted adenine
formula
Prior art date
Application number
AT93906071T
Other languages
English (en)
Inventor
Ernest Beutler
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE192045T1 publication Critical patent/ATE192045T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93906071T 1992-02-19 1993-02-18 Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose ATE192045T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/838,546 US5310732A (en) 1986-02-03 1992-02-19 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
PCT/US1993/001467 WO1993016706A1 (en) 1992-02-19 1993-02-18 Use of substituted adenine derivatives for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE192045T1 true ATE192045T1 (de) 2000-05-15

Family

ID=25277387

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93906071T ATE192045T1 (de) 1992-02-19 1993-02-18 Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose

Country Status (15)

Country Link
US (4) US5310732A (de)
EP (1) EP0626853B1 (de)
JP (1) JP2688113B2 (de)
AT (1) ATE192045T1 (de)
AU (1) AU682818B2 (de)
BR (1) BR9305907A (de)
CA (1) CA2130275C (de)
CH (1) CH684310A5 (de)
DE (1) DE69328474T2 (de)
DK (1) DK0626853T3 (de)
FI (1) FI943805L (de)
HU (1) HU218656B (de)
NO (2) NO309025B1 (de)
RU (1) RU2130308C1 (de)
WO (1) WO1993016706A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5624913A (en) * 1991-04-05 1997-04-29 Wisconsin Alumni Research Foundation Method reducing TNF-alpha in mammals with cerebral malaria
EP0642347A4 (de) * 1992-05-19 1997-06-18 Scripps Research Inst Verwendung von 2-halo-adeninderivaten als therapeutische wirkstoffe gegen chronisch-myeloische leukämie.
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US7094597B1 (en) 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
JPH10505323A (ja) * 1994-05-26 1998-05-26 ザ スクリップス リサーチ インスティテュート ２−ハロ−２’−デオキシアデノシンによる炎症性腸疾患の治療
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996003134A1 (en) * 1994-07-21 1996-02-08 Thomas Jefferson University Treatment of diarrhea with 2-substituted adenosine derivatives
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
US5641757A (en) * 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
PL321431A1 (en) * 1994-12-22 1997-12-08 Ortho Pharma Corp Soluble 2-chloro-2'deoxyadenosine compositions
AU762821B2 (en) * 1994-12-22 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. 'Soluble 2-chloro-2'-deoxyadenosine formulations'
HUP9702408A3 (en) * 1995-02-10 2000-08-28 Schering Ag Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
AU3851601A (en) * 2000-02-18 2001-08-27 Southern Res Inst Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-9h- purin-6-amine
SE516067C2 (sv) * 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
BR0115246A (pt) 2000-11-01 2005-04-26 Univ California Peptìdeos imunomoduladores derivados de proteìnas de choque e seu uso
WO2002078446A1 (en) * 2001-03-29 2002-10-10 Bioenergy Inc. Composition to reduce exercise-induced swelling of joints
US7528247B2 (en) * 2001-08-02 2009-05-05 Genzyme Corporation Process for preparing purine nucleosides
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
WO2004029025A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
EP1551386A4 (de) * 2002-09-27 2009-03-25 Bioenvision Inc Verfahren und zusammensetzungen zur behandlung von lupus mit clofarabin
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
ES2584183T3 (es) * 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
WO2004087101A2 (en) * 2003-03-28 2004-10-14 Ivax Corporation Oral formulations of cladribine
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
WO2005009971A1 (ja) * 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
EP1699459B1 (de) * 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション，インコーポレイテッド Ｆｃ領域変異体
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
SI1835922T1 (sl) * 2004-12-22 2009-10-31 Merck Serono Sa Kombinacijsko zdravljenje multiple skleroze
PL2805723T3 (pl) * 2004-12-22 2018-04-30 Merck Serono Sa Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
US8658622B2 (en) * 2005-01-14 2014-02-25 Regents Of The University Of California Methods and compositions for preventing and treating a disease related to glycan dysregulation
RU2393866C2 (ru) * 2005-03-17 2010-07-10 Проекто Де Биомедисина Сима, С.Л. Применение 5'-метилтиоаденозина (мта) для предотвращения и/или лечения аутоиммунных заболеваний и/или отторжения трансплантата
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
US8126690B2 (en) * 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2343074A1 (de) 2009-12-23 2011-07-13 Merck Serono S.A. Verwendung von Purinanaloga zur Behandlung von Atemwegserkrankungen
WO2012022740A1 (en) 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis
US12590955B2 (en) 2013-03-15 2026-03-31 Zeon Corporation Methods and systems for processing particles
CN113512522A (zh) 2013-03-15 2021-10-19 普林斯顿大学理事会 用于高通量纯化的方法和设备
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
US11493428B2 (en) 2013-03-15 2022-11-08 Gpb Scientific, Inc. On-chip microfluidic processing of particles
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
EP3215149A4 (de) 2014-11-06 2018-06-27 Northwestern University Hemmung der motilität von krebszellen
AU2016311278B2 (en) * 2015-08-24 2021-03-25 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
JP2024508151A (ja) 2021-03-03 2024-02-22 アレス トレーディング ソシエテ アノニム 自己免疫疾患治療のためのｄｍｄを使用する改善された治療法、並びに該治療法を予測及び／又は最適化するためのバイオマーカー

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1572068C3 (de) * 1966-03-12 1976-01-08 Hoechst Ag, 6000 Frankfurt Lichtempfindliche Schicht zur Herstellung von Druckformen
US3472838A (en) * 1967-12-01 1969-10-14 Parke Davis & Co 9 - (beta - d - arabinofuranosyl) - 6 - (amidino) purine compounds and methods for their production
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
GB8708050D0 (en) * 1987-04-03 1987-05-07 Wellcome Found Therapeutic nucleosides
NZ226672A (en) * 1987-10-30 1991-07-26 Hoffmann La Roche 6-amino-9-(2,3-dideoxy-2-fluoro-b-d-threopentofuranosyl)-9h-purine derivatives and pharmaceutical compositions
GB8725466D0 (en) 1987-10-30 1987-12-02 Hoffmann La Roche Purine derivatives
FI895447A7 (fi) * 1988-03-16 1989-11-15 Scripps Clinic And Res Foundation Substituoidut terapeuttisina aineina käytettävät adeniinijohdannaiset
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids

Also Published As

Publication number Publication date
CA2130275C (en) 1999-06-29
CH684310A5 (de) 1994-08-31
CA2130275A1 (en) 1993-09-02
NO942765L (no) 1994-09-13
RU94038043A (ru) 1996-11-20
FI943805A0 (fi) 1994-08-18
EP0626853B1 (de) 2000-04-26
AU682818B2 (en) 1997-10-23
NO20000762L (no) 1994-09-13
RU2130308C1 (ru) 1999-05-20
US5310732A (en) 1994-05-10
US5506213A (en) 1996-04-09
HUT68030A (en) 1995-05-29
AU3724993A (en) 1993-09-13
JPH07507540A (ja) 1995-08-24
US5541164A (en) 1996-07-30
NO942765D0 (no) 1994-07-25
DE69328474D1 (de) 2000-05-31
DK0626853T3 (da) 2000-08-07
WO1993016706A1 (en) 1993-09-02
EP0626853A1 (de) 1994-12-07
DE69328474T2 (de) 2000-09-28
NO309025B1 (no) 2000-12-04
US5506214A (en) 1996-04-09
NO20000762D0 (no) 2000-02-16
JP2688113B2 (ja) 1997-12-08
HU9402392D0 (en) 1994-10-28
HU218656B (hu) 2000-10-28
FI943805A7 (fi) 1994-10-19
FI943805L (fi) 1994-10-19
NO322328B1 (no) 2006-09-18
BR9305907A (pt) 1997-10-21

Similar Documents

Publication Publication Date Title
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
ATE251141T1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69109125D1 (de) Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DK0636025T3 (da) Forbindelser, der er egnede til behandling af allergiske og inflammatoriske sygdomme
DK165003C (da) Chlorsulfat
PH22960A (en) 2-pyrimidinyl-1-piperazine derivatives
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
KR900700495A (ko) 치료제로서 유용한 치환된 아데닌 유도체
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
RU94038063A (ru) 3-фенилуреидо-азепин-2-оны и -бензазепин-2-оны, способы их получения, промежуточные соединения, фармацевтические композиции и способы лечения
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE59101581D1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE69802828D1 (de) Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen
ATE96667T1 (de) Verwendung von heterocyclischen verbindungen zur behandlung von depressionen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties